The use of biochemical markets of bone turnover in osteoporosis

Osteoporosis International

Volumn 11, Issue SUPPL. 6, 2000, Pages

  Delmas, P D ^a   Eastell, R ^b   Garnero, P ^c   Seibel, M J ^d   Stepan, J ^e  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c INSERM   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN TYPE 1; CORTICOSTEROID; DEOXYPYRIDINOLINE; GALACTOSYL HYDROXYLYSINE; GLUCOSYLGALACTOSYLHYDROXYLYSINE; HORMONE; HYDROXYLYSINE; HYDROXYPROLINE; IBANDRONIC ACID; LYSINE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; OSTEOCALCIN; PAMIDRONIC ACID; PROCOLLAGEN; PYRIDINOLINE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIALOPROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ESTROGEN; RALOXIFENE;

BONE ATROPHY; BONE METABOLISM; BONE TURNOVER; DATA ANALYSIS; DEMOGRAPHY; DRUG USE; FRACTURE; HUMAN; NORMAL VALUE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; RISK; STEROID THERAPY; TREATMENT OUTCOME; BLOOD; BONE DENSITY; BONE REGENERATION; BONE REMODELING; FEMALE; METABOLISM; NOMENCLATURE; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PERIODICITY; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; URINE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE REGENERATION; BONE REMODELING; BONE RESORPTION; DIPHOSPHONATES; ESTROGENS; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PERIODICITY; PROGNOSIS; RALOXIFENE; RISK ASSESSMENT; TERMINOLOGY;

EID: 0034526072     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980070002     Document Type: Review

References (78)

1. Automated differential isoenzyme analysis II. The fractionation of serum alkaline phosphatase into liver, intestinal, and other components
2. 1999 Vitamin K dependent proteins of bone and cartilage
3. Bone gla protein (osteocalcin) assay standardization report
4. Procollagen type I carboxyterminal extension propeptide in serum as a marker of collagen biosynthesis in bone
5. Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption
6. Radioimmunoassay for the pyridinoline cross-linked carbxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation
7. Immunoassay for quantifying type I degradation products in urine evaluated
8. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
9. Measurement of biochemical markers of bone resorption
10. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease
11. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies
12. Standardization of biochemical markers of bone turnover
13. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability
14. Age-related changes in bone turnover in men
15. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: A population-based study
16. Changes in bone mass and bone turnover following distal forearm fracture
17. The effect of pregnancy on bone density and bone turnover
18. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: Effect of sex, age and metabolic bone disease
19. Decreased bone turnover in oral contraceptive users
20. The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects
21. The effect of calcium supplementation on the circadian rhythm of bone resorption
22. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption
23. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women
24. Seasonal variation of biochemical indexes of bone turnover: Results of a population based study
25. The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women
26. Variability and response of urinary resorption markers to hormone replacement therapy
27. Serum Crosslaps for monitoring the response in individuals undergoing antiresorptive therapy
28. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women
29. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis
30. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links
31. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
32. Bone loss and biochemical indices of bone remodeling in surgically-induced postmenopausal women
33. Urinary excretion of pyridinium cross-links in healthy women: The long-term effects of menopause and oestrogen/progesterone therapy
34. Plasma BGP: An indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women
35. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
36. Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers
37. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study
38. The contribution of bone loss to postmenopausal osteoporosis
39. Sex steroids, bone mass, and bone loss: A prospective study of pre-, peri-, and postmenopausal women
40. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study
41. Determinants of bone loss in elderly men and women: A prospective population-based study
42. Can biochemical markers predict bone loss at the hip and spine?. A 4-year prospective study of 141 early postmenopausal women
43. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
44. Biochemical markers of bone turnover reflect femoral bone loss in elderly women
45. Determinants of bone loss from the femoral neck in women of different ages
46. Biochemical markers of bone remover and prediction of hip bone loss in older women: The study of osteoporotic fractures
47. Impairment of bone turnover in elderly women with hip fracture
48. Serum osteocalcin during fracture healing in elderly women with hip fracture
49. Relationship of bone turnover to bone density and fractures
50. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study
51. Markers of bone resorption predict hip fracture in elderly women: The Epidos prospective study
52. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study
53. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study
54. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture. A 15 year follow-up study
55. Afternoon sampled serum type I collagen breakdown product (serum CTX) predicts hip fracture in elderly women: Results of the EPIDOS study
56. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women
57. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up study
58. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: The EPIDOS study
59. Which fractures are associated with high bone resorption in elderly women? The Rotterdam Study
60. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study
61. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
62. Hormone replacement therapy in postmenopausal women: Urinary N-telopetide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
63. Biochemical markers of bone turnover to monitor the bone mass response to postmenopausal hormone replacement therapy
64. Comparison of new biochemical markers of bone turnover in late postemenopausal osteoporotic women in response to alendronate treatment
65. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double blind, placebo controlled study and 1-year follow-up)
66. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
67. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
68. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment
69. Early changes in biochemical maficers of bone turnover predict the long term response to alendronate therapy in representative elderly women: A randomized clinical trial
70. Monitoring individual response to hormone replacement therapy with bone markers
71. Early response in biochemical markers predicts long-term response in bone mass during hornlone replacement therapy in early postmenopausal women
72. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
73. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in early postmenopausal intervention cohort of study
74. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical markers of bone turnover
75. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy
76. Six months changes in biochemical markers predict 3-year response in vertebral fracture rate in postmenopausal, osteoporotic women: Results from the MORE study